Grants Search Results

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

New Mexico is a unique state with a largely rural, underserved, and multicultural patient population. This grant supports a clinical research professional to ensure that more kids can be treated on clinical trials, often their best hope for a cure. Additionally, with increased enrollment of our unique patient population in these national and international clinical trials the University of New Mexico Pediatric Oncology Division will increase the diversity of patient representation in these trials.

Developing new therapies from medicine to procedures is the best way to cure cancer and save lives. Clinical trials are research studies involving people of all ages to see if a new drug or medical device is safe and effective. One of the nation’s top children’s hospitals for cancer care, Lurie Children’s offers more pediatric clinical trials than any other hospital in the state. With more studies, their specialists have many options when treating a child with cancer. The success of a clinical trial depends on trained clinical research professionals (CRPs) to manage the study, from enrolling participants to reporting data in a timely and accurate manner. Like many healthcare professionals, CRPs are in high demand due to labor shortages and a very competitive marketplace. With more resources, we can better recruit, train and retain invaluable CRPs so we can provide every child with cancer access to innovative new therapies. This grant supports a clinical research coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The grant is named in honor of the Do It for Dominic Fund. This Hero Fund was created in memory of Dominic Cairo, who died from Non-Hodgkin Lymphoma at the age of 8. His family and friends continue to focus their efforts on raising funds and supporting St. Baldrick’s in the effort find cures for childhood cancers in the hopes that no child ever has to go through what Dominic had to endure.

This grant supports a survivorship and Adolescent Young Adult (AYA) Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded one project. Relapsed or refractory neuroblastoma is the most common extracranial solid tumor found in Hong Kong pediatric cancer patients; however there is no standard therapy yet, and the 5-year overall survival after disease relapse was only about 20%. This clinical study aims to evaluate the efficacy and safety of the treatment of quadruple immunotherapy with the NK cells, anti-GD2 antibody, cytokines and RXRg agonist spironolactone, and also the NK cell chimerism and persistence after adoptive NK cell transfer, in order to examine if this treatment could become a therapeutic option for cases in Hong Kong.

This grant supports a pediatric-focused Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a pediatric-focused Clinical Research Coordinator. Through this support, Golisano Children's Hospital is able to offer the children of central New York a wide variety of childhood cancer clinical trials so that children do not need to leave the region to attain this level of care. This is especially important for smaller, more rural centers like this one.

This grant supports an Adolescent Young Adult (AYA) clinical research professional to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a clinical research professional to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports an early drug development program clinical research assistant to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Ewing sarcoma, an aggressive bone cancer that occurs in children and young adults, is caused by an abnormal chimeric protein (EWS-FLI1) that prevents cells from maturing into normal connective tissues through a process known as cell differentiation. How EWS-FLI1 acts to stop differentiation, however, remains an enigma. To solve this problem, Dr. Ludwig uses powerful gene editing tools to systematically turn the EWS-FLI1 protein up or down, then measures whether such changes allow cancer cells to behave more normally. The information gained from this research is expected to lead to new anti-cancer treatments for adolescents and young adults battling Ewing sarcoma.

This grant is named for The Shohet Family Fund for Ewing Sarcoma Research. Noah was diagnosed with Ewing sarcoma in his freshman year in college. After limb salvage surgery and chemotherapy, he was able to return to school. Two years later, Noah relapsed and sadly passed away. This Hero Fund honors his courageous fight and hopes to raise funds for Ewing sarcoma research.

The majority of children with newly diagnosed Burkitt lymphoma (BL) are cured. Unfortunately, the outcome is poor for patients whose disease returns (relapse). The relapse is caused by multiple reasons but mainly is due to drug resistance and suppression by the tumor surroundings. Novel therapeutic approaches are urgently needed. Natural killer (NK) cells can attack cancer cells. Dr. Cairo is developing immunotherapeutic agents to enhance the functions of NK cells to kill BL. Expanded NK cells will be modified by genetic techniques to specifically target CD20 and a special protein will be developed to bind to another surface protein CD19 on BL. A virus will be created to secrete IL21 to enhance NK persistence and function. If successful, the combinatorial therapies will become available to pediatric BL patients in the clinical setting and would offer a potentially more effective and less toxic therapeutic approach, ultimately leading to improved survival.

This grant is funded by and named for Jack's Pack - We Still Have His Back, a St. Baldrick's Hero Fund. Jack Klein was a ten year old who loved life, laughing and monkeys. During his illness, his community of family and friends near and far rallied around him under the moniker "Jack's Pack". Their slogan was "We have Jack's Back". After Jack succumbed to Burkitt's Lymphoma, his "pack" focused their energy and efforts to funding a cure...just as Jack would have wanted.

There has been little recent progress in treating Ewing sarcoma, a pediatric tumor involving bone. Dr. Stegmaier and colleagues have used a technology called CRISPR to identify urgently needed, new therapeutic targets for this disease. They prioritized a class of targets which are expressed in immature but not mature tissues. These proteins are often abnormally re-expressed in cancers such as Ewing sarcoma. Thus, drugs targeting these proteins would be expected to have minimal toxicity. The Stegmaier lab identified the target IGF2BP1 as a top selective gene dependency in Ewing sarcoma; deletion of IGF2BP1 was more deleterious to Ewing sarcoma than all other cancer types screened. Importantly, IGF2BP1 is not expressed in most normal human cells. Dr. Stegmaier will validate IGF2BP1 as a therapeutic target in Ewing and will determine the mechanisms by which Ewing sarcoma cells rely on IGF2BP1 for growth. With IGF2BP1 chemical inhibitors in development, this project has exciting translational potential for patients with Ewing sarcoma.

This grant is funded by and named for The Ben Brandenburg Fund for Ewing Sarcoma Research. Ben passed away at the age of 15. He is remembered for his quick wit, indomitable spirit and bravery. This fund is his lasting legacy and ensures that research is funded so fewer children will have to suffer from Ewing Sarcoma.

Adoptive immunotherapy has demonstrated unprecedented success in the treatment of pediatric leukemia. Extending its therapeutic potential to other pediatric malignancies such as glioblastoma (GBM) has proved challenging. In this therapy, T cells are isolated from a patient, expanded outside of the body, and genetically modified prior to reinfusion. The ability of these T cells to recognize and eliminate cancer cells is improved by expressing a protein (CAR) on the T cell surface. An important challenge is to minimize the manipulation of patients' T cells outside the body. Prolonged culture compromises their efficacy. Dr. Ghassemi developed approaches to generate CAR T cells in 1 day. These cells have increased potency. She is combining this recent development with a metabolic strategy to overcome the metabolic nature of tumor environment. This synthetic advancement combined with the production of CAR T cells in 1 day will lead to superior CAR T cells for cellular immunotherapies against pediatric GBM.

This grant is funded by and named for the Be Brooks Brave Fund. Despite his diagnosis at age 5 with inoperable brain and spinal tumors, Brooks taught so many people what life is truly about--love. He was BRAVE beyond his years with an inspiring “faith over fear” attitude. This Hero Fund hopes to raise money for high-grade glioma research so no other family will hear the words, “there is no cure”.

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk type of B-ALL. Children and adolescents/young adults with Ph-like ALL have greater than 60% relapse risk and experience significant mortality with best-available chemotherapy. Emerging data suggest that patients with Ph-like ALL are more likely to develop immunotherapeutic resistance to treatments. Dr. Tasian, and Dr. Terry Fry at the University of Colorado, and their colleagues are testing whether a new CAR T cell immunotherapy that they developed will decrease the risk of relapse for patients with Ph-like ALL. This work will be the groundwork to translate findings into a phase 1 clinical trial. This grant is supported by The Ty Louis Campbell (TLC) Foundation. TLC was created in memory of Ty, who lost his 2-year battle with brain cancer just days after his fifth birthday. TLC funds innovative research and clinical trials specifically geared toward the treatment of the deadliest childhood cancers (including brain and spinal cord tumors). TLC seeks less toxic, more effective treatments that are specifically designed for children fighting cancer. Their ultimate mission is to help fund the intelligence and technology that will uncover new ways to cure children with cancer.

Based on progress to date, Dr. Faulk was awarded a new grant in 2024 and 2025 to fund an additional year of this Scholar grant. Infant leukemia is an aggressive cancer with a very poor prognosis. The leukemia cells in most of these patients have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another (this is called "rearranged"). A drug named SNDX-5613 has been developed that directly targets the changes that occur in a cell with a KMT2A rearrangement to specifically kill these leukemia cells, and it has shown promise in treating adult leukemia patients with a KMT2A rearrangement. An upcoming clinical trial will combine SNDX-5613 with traditional chemotherapy for children with leukemia with a KMT2A rearrangement that has come back (relapsed) or proven resistant to typical treatment (refractory). In addition to testing the safety and efficacy of SNDX-5613, studies will be done on patients’ blood and bone marrow samples to better understand how the drug functions in fighting leukemia. This trial represents the next step in evaluating this promising new targeted drug for these deserving patients, and the associated studies are key to helping us understand more about the biology of this leukemia and how to best target it.

This grant is named for the Oh Danny Boy, I Love You So: The Danny O'Brien Rhabdoid Tumor Research Fund. Danny O’Brien was just 5 months old when he was diagnosed with a malignant rhabdoid tumor on his liver. This cancer is extremely rare and aggressive. He endured chemotherapy to shrink the tumor for surgery, but the treatment was not effective. At the tender age of 9 months, Danny passed away. Fortunately, he knew nothing but love and affection all of his short life. This fund honors Danny’s courage and his unconditional love even in the midst of his battle with cancer.